Genomics, personalized medicine and cancer practice

Clinical Biochemistry

Volumn 45, Issue 6, 2012, Pages 379-381

  Dancey, Janet ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

Cancer Genomics; Genome Sequencing; Molecular Profiling; Personalized Medicine; Targeted Therapies

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRANSCRIPTOME; TRASTUZUMAB;

BIOINFORMATICS; BREAST CANCER; CANCER DIAGNOSIS; CANCER GENETICS; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER RESEARCH; CANCER THERAPY; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DRUG RESEARCH; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOME; GENOMICS; GENOTYPE; HUMAN; MEDICAL DECISION MAKING; MOLECULAR GENETICS; MOLECULARLY TARGETED THERAPY; NOTE; PERSONALIZED MEDICINE; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TECHNOLOGY; TUMOR GENE;

CLINICAL TRIALS AS TOPIC; GENETIC TESTING; GENOMICS; HUMANS; INDIVIDUALIZED MEDICINE; MOLECULAR TARGETED THERAPY; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84858423136     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2012.03.003     Document Type: Note

References (17)

1. Stricker T., Catenacci D.V., Seiwert T.Y. Molecular profiling of cancer-the future of personalized cancer medicine: a primer on cancer biology and the tools necessary to bring molecular testing to the clinic. Semin Oncol 2011, 38:173-185.
2. Vaske C.J., Benz S.C., Sanborn J.Z., et al. Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM. Bioinformatics 2010, 26:i237-i245.
3. Hudson T.J., Anderson W., et al. International network of cancer genome projects. Nature 2010, 464:993-998. International Cancer Genome Consortium.
4. Meldrum C., Doyle M.A., Tothill R.W. Next-generation sequencing for cancer diagnostics: a practical perspective. Clin Biochem Rev 2011, 32:177-195.
5. Gonzalez-Angulo A.M., Hennessy B.T., Mills G.B. Future of personalized medicine in oncology: a systems biology approach. J Clin Oncol 2010, 28:2777-2783.
6. Schilsky R.L. Personalized medicine in oncology: the future is now. Nat Rev Drug Discov 2010, 9:363-366.
7. Rothberg J.M., Hinz W., Rearick T.M., et al. An integrated semiconductor device enabling non-optical genome sequencing. Nature 2011, 475:348-352.
8. Van Schaeybroeck S., Allen W.L., Turkington R.C., et al. Implementing prognostic and predictive biomarkers in CRC clinical trials. Nat Rev Clin Oncol 2011, 8:222-232.
9. McShane L.M., Altman D.G., Sauerbrei W., et al. REporting recommendations for tumor MARKer prognostic studies (REMARK). Nat Clin Pract Oncol 2005, 2:416-422.
10. Tran B., Dancey J.E., Bedard P.L., et al. Feasibility Study of Molecular Profiling (MP) in Patients (Pts) with Advanced Solid Cancers using Targeted Mutation Analysis and Targeted Exome Sequencing. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics:Abstract 11-A-188-AACR 2011.
11. Ross J.S., Lipson D., Yelensky R., et al. Comprehensive next-generation sequencing for clinically actionable mutations from formalin fixed cancer tissues. J Clin Oncol 2011, 29. (Suppl.):Abstract 10564.
12. Dancey J.E., Bedard P.L., Onetto N., et al. The genetic basis for cancer treatment decisions. Cell 2012, 148:409-420.
13. Peach J., Hemsley F.M., Jones L.K., et al. The Cancer Research UK Stratified Medicine Program http://science.cancerresearchuk.org/prod_consump/groups/cr_common/@fre/@gen/documents/generalcontent/strat-med-leaflet-techno-hub.pdf.
14. Khleif S.N., Doroshow J.H., Hait W.N. AACR-FDA-NCI Cancer Biomarkers Collaborative consensus report: advancing the use of biomarkers in cancer drug development. Clin Cancer Res 2010, 16:3299-3318.
15. An Annual Plan and Budget Proposal for Fiscal Year 2012 2009, The Nation's Investment in Cancer Research, U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, National Institutes of Health.
16. Food and Drug Administration: FDA approves Xalkori with companion diagnostic for a type of late-stage lung cancer Press Release August 25, 2011, 2011.
17. Chabner B.A. Early accelerated approval for highly targeted cancer drugs. N Engl J Med 2011, 364:1087-1089.